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1Kosan Biosciences, Inc.
3832 Bay Center Place have excellent activity in cell-based cytotoxicity assays
[7, 8], are less reactive toward nucleophiles, and showHayward, California 94545
2 Department of Biochemistry and Biophysics reduced hepatotoxicity (vida infra). One of these com-
pounds, 17-allylamino-17-demethoxygeldanamycin (17-University of California, San Francisco
San Francisco, California 94143 AAG; NSC 330507), demonstrated antitumor activity in
vivo and was brought into Phase I clinical trials. How-3 Dipartimento di Scienze Farmaceutiche
Universita di Modena e Reggio Emilia ever, 17-AAG’s relative water insolubility makes it diffi-
cult to formulate, and early reports indicate some degreeVia Campi 183 41100 Modena
Italy of hepatotoxicity that might be averted by more potent
analogs. Preclinical evaluation of 17-desmethoxy-17-
N,N-dimethylaminoethylamino-geldanamycin (17-DMAG;
NSC 707545) showed that it is more potent and waterSummary
soluble than 17-AAG, is active against in mouse-human
xenografts, and has excellent oral bioavailability [9].Hsp90 is an attractive chemotherapeutic target be-
cause it chaperones the folding of proteins found in Here we report the three-dimensional structure of the
N-terminal domain of human Hsp90 complexed withmultiple signal transduction pathways. We describe
the 1.75 A˚ resolution crystal structure of human 17-DMAG determined by X-ray crystallography and re-
fined to 1.75 A˚ resolution. We also report a targetedHsp90 (residues 9–236) complexed with 17-desmeth-
oxy-17-N,N-dimethylaminoethylamino-geldanamycin molecular dynamics study and an energy analysis of the
conformational changes that convert the free into the(17-DMAG). The structure revealed an altered set of
interactions between the 17-substituent and the pro- bound conformation of geldanamycin. Taken together,
the results presented here provide a structural templatetein compared to geldanamycin and the 17-dimeth-
ylaminoethyl moiety pointing into solvent, but other- for further development of drugs based on the geldana-
mycin scaffold.wise was similar to that reported for the complex with
geldanamycin. Targeted molecular dynamics simula-
tions and energetic analysis indicate that geldana-
Results and Discussionmycin undergoes two major conformational changes
when it binds Hsp90, with the key step of the conver-
Overall Protein Structuresion being the trans to cis conformational change of
The 1.75 A˚ resolution crystal structure of 17-DMAG com-the macrocycle amide bond. We speculate that 17-
plexed to the N-terminal domain of human Hsp90 wasDMAG analogs constrained to a cis-amide in the
determined using molecular replacement (Table 1). Al-ground state could provide a significant increase in
though the crystallization conditions of the 17-DMAGaffinity for Hsp90.
complex (MPD/pH 4.5) were different from those of the
previously published geldanamycin complex (PEG/pHIntroduction
8.5) [4], crystals of the 17-DMAG complex grew in the
same space group (P21) with unit cell dimensions (a Hsp90 is an essential protein that chaperones multiple
47.7 A˚; b 41.7 A˚; c 56.0 A˚;  102.8) similar to thosegrowth-regulatory signaling proteins, including protein
of the geldanamycin complex structure (a  53.7 A˚; b kinases [1] and transcription factors [2, 3]. Geldana-
44.3 A˚; c 54.6 A˚;116.1). The final model comprisesmycin (Figure 1A), a benzoquinone ansamycin antibiotic,
residues 9–223, 277 waters, 1 molecule of 17-DMAG, 2binds to the N-terminal domain ATP binding site of
MPD molecules, and 2 acetate molecules. All residuesHsp90 [4, 5], inhibiting the chaperone activity of the
lie within the allowed regions of the Ramachandran plot.protein. This leads to disruption of the Hsp90 client
There is a single amino acid difference between thisprotein complexes and subsequent ubiquitination and
structure and the previously published human Hsp90degradation by the proteosome of the client proteins.
structure [4]. The 17-DMAG•Hsp90 structure shows aBecause the Hsp90 client proteins are so important in
serine at position 63 rather than the threonine reportedsignal transduction and transcription, geldanamycin and
in the geldanamycin•Hsp90 complex. The presence ofits analogs have the potential of serving as chemothera-
Ser63 in our Hsp90 was confirmed by DNA sequencing,peutic agents in a number of diseases.
and is likewise present in the authentic full-length Hsp90Although geldanamycin displays high potency in cyto-
clone reported by Hickey et al. [10]. We presume thattoxicity assays, it showed significant hepatotoxicity in
the serine and threonine variants in the structural modelspreclinical trials [6]. Likely, this can be attributed to the
reflect the origin of the respective clones.
In the complex with 17-DMAG, the overall structure*Correspondence: santi@kosan.com
of the N-terminal domain of human Hsp90 adopts the4 Current address: Danforth Plant Science Center, 975 North Warson
Rd., St. Louis, Missouri 63132. “open” ATP binding site conformation that allows ligand
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Figure 2. Structure of the Hsp90•17-DMAG Complex
Ribbon representation of the N-terminal domain of human Hsp90
( helices, gold;  strands, blue) showing the location of 17-DMAG
Figure 1. Geldanamycin and Analogs (green ball-and-stick model). The N and C termini residues are indi-
cated.(A) Structures of geldanamycin (R  CH3O-) and 17-substituted
analogs (17-AAG, R  CH2CHCH2NH- and 17-DMAG, R 
(CH3)2NCH2CH2NH-).
17-DMAG Binding in the Active Site(B) Conformations of geldanamycin in the free (left) and the Hsp90-
Clear electron density in the ATP binding cleft of Hsp90bound (right) forms.
indicated unambiguously the location and orientation of
17-DMAG (Figure 3A). The site where 17-DMAG binds
is centered between three  helices (2, 4, and 7) onbinding [4] (Figure 2). The 17-DMAG complex structure
is similar to the geldanamycin complex structure [4] with the face of the core antiparallel  sheet structure (Figure
2). As expected, the interactions between the residuesa root-mean square deviation (RMSD) of the C-atoms
of 0.77 A˚. The largest local coordinate shifts of 2–4 A˚ of the binding site and the ansa ring of 17-DMAG are
similar to those observed with geldanamycin [4]. Like-between the protein backbones of the two structures
occur between residues 34–37, 115–128, and 156–157. wise, the network of water molecules observed at the
bottom of the binding site in the geldanamycin complexDifferent loop conformations account for changes in the
positions of residues 34–37 and 156–157. With residues is conserved in the 17-DMAG structure.
Embedded in the ATP/geldanamycin site, the ansa115–128, the changes result from different crystal con-
tacts between the two structures. ring of 17-DMAG adopts a C-like conformation with the
Table 1. Data Collection and Refinement Statistics
Space group P21
Cell dimensions a  47.7 A˚; b  41.7 A˚; c  56.0 A˚;   102.8
Resolution 10–1.75 A˚
Reflections (total/unique) 97,350/21,560
Completeness (highest shell) 99.2% (97.9%)
I/ (highest shell) 5.3 (2.2)
Rsyma (highest shell) 6.5% (31.7%)
Rcrystb/ Rfreec 18.4%/21.9%
Rms. deviation bond lengths 0.005 A˚
Rms. deviation bond angles 1.3
Average B factor, main chain/side chain 14.9 A˚2/18.8 A˚2
Average B factor, water 32.4 A˚2
Average B factor, 17-DMAG/MPD/acetate 13.5 A˚2/46.1 A˚2/53.9 A˚2
a Rsym  |Ih 	 Ih|/Ih, where Ih is the average intensity over symmetry equivalent reflections.
b Rcryst  |Fo 	 Fc|/Fo, where summation is over the data used for refinement.
c Rfree is defined the same as Rcryst but was calculated using 5% of data excluded from refinement.
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Figure 3. Binding of 17-DMAG
(A) Stereoview of the composite omit, cross-
validated, sigma-A weighted map electron
density (contoured at 1.2 ) of 17-DMAG.
(B) Stereoview of residues in the binding cleft.
17-DMAG (green) and waters (red spheres)
are also shown. Hydrogen bond interactions
are indicated by dotted lines (rose).
carbamate group at the bottom back of the site and the at positions 6 and 12 form hydrogen bonds with the
amide nitrogen of Asn106 and a water molecule buriedbenzoquinone ring at the solvent-exposed top of the
pocket (Figure 3B). Multiple protein-ligand interactions at the back of the site, respectively. Likewise, the amine
of Lys58 interacts with the C11-hydroxyl group. Finally,(Figure 4) lock the macrocyle of 17-DMAG in a conforma-
tion similar to that of geldanamycin. The C7-carbamate the C18-ketone hydrogen bonds with the amine of
Lys112 and the C21-ketone contacts a water moleculegroup and a water molecule form a hydrogen bond net-
work with the side chains of Asp93 and Thr184 and the that in turn interacts with the amide oxygen of Asn51.
Positioned at the top of the ATP/geldanamycin bind-backbone nitrogens of Gly95 and Gly97. Extensive van
der Waals contacts between the ansa ring of 17-DMAG ing site, the 17-dimethylaminoethylamino substituent of
17-DMAG points into solvent. The electron density isand binding pocket residues are supplemented by addi-
tional hydrogen bonds with other substituents of the weaker for the dimethylaminoethyl group (Figure 3A)
and the B-factors are higher for the atoms of this sidemacrocycle. The amide of the ansa ring interacts with
the backbone nitrogen of Phe138 and a water molecule chain (average of 30.3 A˚2 ) compared to those of the ansa
ring (average of 10.8 A˚2 ) also reflecting this moiety’son the surface of the binding site. The methoxy groups
Figure 4. Interactions between 17-DMAG
and Hsp90
Schematic drawing of interactions between
17-DMAG and the ATP binding site of human
Hsp90. Hydrogen bonds are shown as dot-
ted lines with distances given in angstroms.
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flexibility and its solvent exposure. Although the 17- Starting from the free conformation, the 0–360 ps time
interval is characterized by the folding of the benzoqui-position side chain of 17-DMAG is longer than the C17-
methoxy group of geldanamycin, the dimethylaminoe- none over the macrocycle. This folding is accompanied
by conformational changes at the C10–C15 and thethylamino moiety is oriented into solvent and does not
interfere with binding of the ligand to the target site. This C2–C6 regions of the polyketide. The conformation gen-
erated (Intermediate 1 in Figure 5), which lasts betweenobservation corroborates structure-activity relationship
studies demonstrating that small alkylamino groups, 330 ps and 500 ps, is still significantly open and the
amide bond is still trans. Remarkably, it is not possibleeither unfunctionalized or bearing hydroxyl or amino
moieties, are the best inhibitors in cell-based toxicity to dock this conformation into Hsp90 without severe
steric conflicts with active site residues. Conversion ofassays [7, 8].
There is a rearrangement of protein-ligand interac- the amide bond to the cis form occurs at about 550 ps.
The 360–640 ps frame shows that when the amide bondtions in the binding site accompanying the substitution
of an alkylamino group at the 17-position of 17-DMAG isomerizes to cis, the C11–C15 portion of geldanamycin
moves toward the diene moiety, leading to a highlyfor the methoxy moiety of geldanamycin. In the geldana-
mycin complex, the side chain amine of Lys58 forms packed C-like structure with the C14-methyl and C2-
methyl groups bridging the two halves of the ansa ringhydrogen bonds with both the C11-hydroxyl group and
the C17-methoxy group of the macrocycle. With 17- (Intermediate 2 in Figure 5). The last conformational
change seen at 670 ps involves an axial/equatorial swapDMAG, the amine of Lys58 only hydrogen bonds with
the C11-hydroxyl group, as described above, and a hy- of the C11-hydroxyl and the C12-methoxyl groups. This
rearrangement moves the C11-hydroxyl group closer todrogen bond between the 17-NH group of the substitu-
ent and the carboxylate of Asp54 replaces the interac- the 17-methoxyl group as seen in the 640–800 ps frame.
In the crystal structure of the Hsp90•geldanamycin com-tion between the oxygen of the C17-methoxy group of
geldanamycin and Lys58. With the altered interactions plex, Lys58 bridges these two groups.
Results from the energetic analysis of geldanamycin inin the binding site, the position of the quinone ring shifts
0.5–0.8 A˚ away from Lys58 and toward Asp54. The hy- the free, bound, and the two intermediate conformations
found by TMD are shown in Table 2 for the MM-PBSAdrogen bond between the 17-amino group of 17-DMAG
and Asp54 is the only protein-ligand interaction provided and the molecular orbital AM1 methods. They both pre-
dict that the conformation that binds Hsp90 is less stableby the dimethylaminoethylamino group, since the re-
mainder of the side chain is oriented away from the than the free conformation: the MM-PBSA method by
2.2 kcal mol	1 and the AM1 method by 6.4 kcal mol	1binding site and into solvent. Based on the 17-DMAG
structure, we propose that the 17-alkylamino analogs, (free energy differences in water relative to the free con-
formation, 
Gwater). Intermediates 1 and 2 are 0.4 kcalincluding 17-AAG, bind with the 17-NH group, forming
a hydrogen bond with Asp54, with the remainder of the mol	1 and 4.6 kcal mol	1 (MM-PBSA) and 1.2 kcal mol	1
and 4.5 kcal mol	1 (AM1) less stable than the free confor-side chain pointing into solvent.
mation, respectively. Both methods suggest that the
stability of the bound conformation is favored by a higher
Conformational Changes of Geldanamycin solvation free energy compared to the free conforma-
from the Free to Bound Forms tion. However, they indicate that there is a significant
As described above, the structure of the Hsp90-bound entropic penalty in the bound conformation. Indeed,
macrocycle of 17-DMAG closely resembles that re- while the free and Intermediate 1 conformations are
ported for bound geldanamycin. It adopts a C-like con- significantly open and coherently have larger entropy
formation quite different than the structures of free gel- values (the 
S is even positive for Intermediate 1), Inter-
danamycin [11] or 17-azetidinyl-geldanamycin [12]. In mediate 2 and the bound conformations are highly
the bound conformation, the benzoquinone ring folds packed and have lower entropy values. The decrease
over the macrocycle into a highly compact structure in entropy when going from the free to the bound form
with a remarkable rearrangement of the polyketide back- is 	3.4 cal mol	1 K	1 (MM-PBSA) and 	5.46 cal mol	1
bone. Moreover, although obvious from the crystal K	1 (AM1).
structures but to our knowledge not explicitly mentioned
in previous reports [4, 5], the trans-amide bond of the
free polyketide is bound to the protein as a cis-amide Implications for Inhibitor Design
Several results obtained in this study may be of rele-bond (Figure 1B).
To gain insight into the conformational path taken to vance in future design of inhibitors of the ATPase site
of human Hsp90. First, the structures of the ansa ring ofconvert free geldanamycin into the Hsp90-bound form,
targeted molecular dynamics (TMD) simulations were 17-DMAG and geldanamycin are nearly identical when
bound to Hsp90. Thus, one can be secure in using eitheremployed. Although the time scale of transition in TMD
is arbitrary, the relative order of events in the conforma- structure for conventional structure-based design ap-
proaches toward enhancement of 17-methoxy or 17-alkyl-tional changes is determined by the intrinsic energy sur-
face of the system, and TMD has been highly successful amino analogs. Second, the alkyl moiety of 17-alkylam-
ino-geldanamycins points toward solvent and appearsin modeling conformational changes [13-15]. Figure 5
shows superimpositions of averaged structures col- to be flexible. The speculation that a wide variety of 17-
alkyl substitutions should be tolerated by Hsp90 withoutlected during the time course of an 800 ps TMD simula-
tion, with the stationary points identified along the con- impact is borne out by structure activity relationship
studies at this position [7, 8]. Finally, modeling studiesversion explicitly shown.
Structure of the Hsp90•17-DMAG Complex
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Figure 5. Molecular Dynamics of the Conformational Change of Geldanamycin
Superimposition of averaged structures collected during the 800 ps TMD simulation that converts the free into the bound form of geldanamycin.
In the superimpositions, the initial structures are colored in yellow, and the final structures are colored in cyan. The intermediate conformations
are explicitly shown. For clarity, only the polar hydrogens are shown.
suggest that geldanamycin undergoes two major con- evidence for a large conformational change induced
upon binding comes from isothermal titration calorime-formational changes during the free to bound conver-
sion. The folding of the benzoquinone ring precedes the try experiments, which show that binding of geldana-
mycin to Hsp90 suffers a high entropic penalty, whileamide bond conversion, and two intermediate confor-
mations could be detected. Notably, the folding of the binding of radicicol (which binds without conformational
changes) has a favorable entropic contribution [5]. Thequinone by itself is not sufficient to generate a conforma-
tion likely to bind Hsp90, while the trans-to-cis conver- 
S values of 	3.4 cal mol	1 K	1 (MM-PBSA) and 	5.46
cal mol	1 K	1 (AM1) calculated here compare well withsion appears to be the more relevant step. Experimental
Table 2. Energetic Analysis of the Free, Bound, and Intermediate Conformations of Geldanamycin Found by TMD
H(a) S(b) Gvacuo(c) 
Gsolv(d) Gwater(e) 
H(f) 
S(f) 
Gvacuo(f) 
Gwater(f)
MM-PBSA
Free 52.8  4.8(g) 249.4  1.4 	21.6  4.8 	43.8  1.8 	65.4  4.8 0 0 0 0
Intermediate 1 57.3  4.8 251.5  1.3 	17.7  4.9 	47.3  1.5 	65.0  4.9 4.5 2.1 3.9 0.4
Intermediate 2 61.6  4.9 246.7  0.9 	11.9  4.9 	48.9  1.6 	60.8  4.8 8.8 	2.7 9.7 4.6
Bound 57.5  5.4 246.0  1.7 	15.8  5.4 	47.4  1.6 	63.2  5.4 4.7 	3.4 5.8 2.2
AM1
Free 	173893.6 268.75 	173973.7 	17.3 	173991.0 0 0 0 0
Intermediate 1 	173892.0 269.19 	173972.3 	17.5 	173989.8 1.6 0.44 1.4 1.2
Intermediate 2 	173887.7 264.05 	173966.4 	20.1 	173986.5 5.9 	4.70 7.3 4.5
Bound 	173887.1 263.29 	173965.6 	19.0 	173984.6 6.5 	5.46 8.1 6.4
(a) Enthalpy (kcal mol	1) at 298.15 K.
(b) Entropy (cal mol	1 K	1) at 298.15 K.
(c) Free energy (kcal mol	1) according to G  H	TS
(d) Free energy of solvation (kcal mol	1)
(e) Free energy in water (kcal mol	1) calculated as Gvacuo  
Gsolv
(f) Energy and entropy differences relative to the most stable conformer (kcal mol	1)
(g) Averaged values and standard deviations of the 400 ps trajectory.
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at 37C in 1 l of LB media containing 50 g mL	1 kanamycin untilthe measured value of	6.4 cal mol	1 K	1 (	26.8 J mol	1
A600nm 0.8–1.0. After induction with 1 mM IPTG, cultures were grownK	1 [5]). We speculate that if a geldanamycin analog had
at 30C for 4–6 hr. Cells were pelleted by centrifugation (10,000 g;a constrained cis-amide bond in the ground state, the
10 min.) and resuspended in 50 ml lysis buffer (50 mM Tris-HCl [pH
remainder of the molecule would adopt the C-like con- 8.0], 500 mM NaCl, 20 mM imidazole [pH 8.0], 10% [v/v] glycerol,
formation and bind to the open form of Hsp90 without and 1% [v/v] Tween-20). Following sonication, cell debris was re-
moved by centrifugation (50,000 g; 1 hr) and the supernatant (500the large energy loss required for a conformational
mg protein) loaded by gravity on a 3 ml Ni2-NTA agarose column.change induced by the protein. If all the energy were
After washing with 10 column volumes of lysis buffer and 10 columnconserved by a conformationally restricted analog, one
volumes of wash buffer (lysis buffer minus Tween-20), the boundmight expect increases in affinity of1,000-fold. Studies
protein was eluted in 50 mM Tris-HCl (pH 8.0), 500 mM NaCl, 250
to construct such conformationally constrained analogs mM imidazole (pH 8.0), and 10% (v/v) glycerol. Thrombin (20 g;
are in progress. weight equal to 1/2000 of eluted protein) was added to the His6-
tagged protein (40 mg) and dialyzed overnight at 4C against wash
buffer. Dialyzed protein was passed over a 1 ml Ni2-NTA/benzami-Significance
dine-Sepharose column (1:1 v/v) equilibrated with 20 column vol-
umes of wash buffer. Gel filtration on a Superdex-75 FPLC column
Hsp90 is an essential protein that chaperones the fold- equilibrated with 25 mM Hepes (pH 7.5) and 100 mM NaCl using
ing of multiple growth-regulatory signaling proteins. isocratic conditions for 1.5 column volumes (4 ml fraction size) was
the final purification step. The peak fractions (12 mL) were pooledIn general, disruption of the Hsp90-client protein com-
with typical final yields of 30–35 mg of homogenous protein, asplexes leads to ubiquitinylation of the client proteins
determined by SDS-PAGE. Protein was then concentrated usingand subsequent degradation by the proteosome. Be-
Amicon centrifugal filter units to 35 mg mL	1 and stored at 	80C.
cause the client proteins are so important in signal
transduction and transcription, geldanamycin and its Crystallography
analogs have the potential of serving as chemothera- For cocrystallization with 17-DMAG, 250 l of purified protein (0.341
peutic agents in a number of diseases. Use of geldana- mol) was mixed with 2 ml of 2.1 mM 17-DMAG (6-fold molar excess)
in 25 mM Hepes (pH 7.5) and 100 mM NaCl, then concentrated tomycin and 17-allylamino-17-demethoxygeldanamycin
24 mg mL	1. Crystals grew in 3–5 days at 5C from 2 l hanging(17-AAG) as Hsp90 inhibitors has encountered various
drops of a 1:1 mixture of complexed protein and mother liquorproblems, including hepatotoxicity and formulation
(5%–10% [v/v] 2, 4-methylpentane diol [MPD], 20 mM CaCl2, anddifficulties, thus requiring continued development of 100 mM sodium acetate [pH 4.5]) using the vapor diffusion method.
new compounds. Preclinical evaluation of 17-des- Crystals were dark red/purple in color, suggesting that 17-DMAG
methoxy-17-N,N-dimethylaminoethylamino-geldana- was bound in the active site. Prior to freezing in liquid nitrogen,
crystals were briefly washed with 35% MPD, 20 mM CaCl2, and 100mycin (17-DMAG) shows that it is active against breast
mM sodium acetate (pH 4.5). Diffraction data were collected at 105cancer, lung cancer, and melanoma xenografts; orally
K from a single crystal on beamline 7-1 of the Stanford Synchrotronactive; and has excellent bioavailability. Determination
Radiation Laboratory (  1.08 A˚) using a MAR345 image plate
of the crystal structure of the N-terminal domain of (Table 1). Data were indexed and scaled using MOSFLM [16] and
human Hsp90 complexed with 17-DMAG reveals the SCALA [17]. The structure was solved by molecular replacement
detailed interactions of this compound with the ATP with CNS [18] using the open active site form apoenzyme model
of the N-terminal fragment of human Hsp90 (Ref. 4; PDB1YES).binding site. Furthermore, targeted molecular dynam-
Crossrotation and translation searches yielded a single solution (1ics simulations of the conformational changes that
268.95, 2  30.08, 3  82.65, x  2.56, y  10.53, z  27.35)convert the macrocyclic ring from the free into the
with monitor and packing values of 0.620 and 0.649, respectively,
bound conformation suggest that a geldanamycin an- consistent with the presence of a single monomer in the asymmetric
alog with a constrained cis-amide bond in the ground unit. After rigid-body refinement using CNS (Rcryst42.4%;
state would bind without the large energy and entropy Rfree42.6%), difference electron density indicated the presence of
17-DMAG in the binding site. Following an initial round of simulatedloss required for the conformational change induced
annealing, positional and B-factor refinement (Rcryst30.0%;by the protein, resulting in a significant increase in
Rfree32.3%,), 17-DMAG was added to the model. CNS parameteraffinity. Taken together, these results provide a struc-
and topology files for 17-DMAG were generated using the HIC-
tural template for the development of such conforma- Up Server (http://xray.bmc.uu.se/hicup/menu.html). In subsequent
tionally constrained Hsp90 inhibitors. iterative rounds of manual rebuilding in O [19] and refinement in
CNS, waters were gradually added using CNS with the R-factors
Experimental Procedures converging to those reported in Table 1. All figures were generated
using MOLSCRIPT [20] or BOBSCRIPT (http://www.strubi.ox.ac.uk/
Materials bobscript) and were rendered with POV-Ray (http://www.povray.
The pET-28a expression vector was from Novagen. The Ni2-nitrilo- org). The coordinates and structure factors for the structure reported
triacetic acid (NTA) agarose was purchased from Qiagen. Benzami- in this paper have been deposited in the Protein Data Bank
dine-Sepharose and the HiLoad 16/60 Superdex-75 FPLC column (PDB1OSF).
were from Amersham Biosciences. Thrombin, kanamycin, and iso-
propyl-1-thio--D-galactopyranoside (IPTG) were obtained from Molecular Modeling
Sigma. Amicon centrifugal filter units were purchased from Millipore. Molecular dynamics (MD) simulations were performed with the
sander module of AMBER7 [21], using the Cornell et al. force field
[22] on an IBM-SP3 computer at the Centro Interdipartimentale diCloning, Expression, and Purification
The 0.7 kb DNA fragment corresponding to the N-terminal fragment Calcolo Elettronico of the University of Modena. Silicon Graphics
O2 workstations running MIDAS [23] were used for graphical display.of human Hsp90 [10] (residues 9–236) was excised from pKOS200-
236 (A. Schirmer, unpublished data) by restriction digest with NdeI The atomic charges of geldanamycin were obtained from an electro-
static potential (ESP) fit to the 6-31G* ab initio wave function, usingand XhoI and sub-cloned into pET-28a at the same sites. The re-
sulting construct (pKOS227-126) adds an N-terminal hexahistidine GAUSSIAN98, followed by standard RESP [24] fit. Force-field pa-
rameters consistent with the Cornell et al. parameterization weretag, a thrombin cleavage site, and a methionine residue before resi-
due 9 of human hsp90. Transformed E. coli BL21(DE3) were grown assigned and, in a few cases, derived from conformational analysis
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performed with AM1. To assure that the resulting conformations References
were in agreement with the crystal structures, the free and bound
forms of geldanamycin were energy minimized. The standard gener- 1. Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P.,
Trepel, J., Whitesell, L., Schnur, R., Moyer, J., and Neckers, L.alized Born/surface area (GB/SA) [25, 26] implicit model for aqueous
solvation, with the solvent dielectric set to 80, was used for all (1996). p185erbB2 binds to GRP94 in vivo. Dissociation of the
p185erbB2/GRP94 heterocomplex by benzoquinone ansamy-simulations. The free conformation of geldanamycin was first mini-
mized with 3,000 steps of conjugate-gradient energy minimization, cins precedes depletion of p185erbB2. J. Biol. Chem. 271, 4974–
4977.followed by 200 ps of MD equilibration at 300 K. SHAKE [27] was
not used, and a time step of 1 fs was adopted. After equilibration, 2. Minet, E., Mottet, D., Michel, G., Roland, I., Raes, M., Remacle,
J., and Michiels, C. (1999). Hypoxia-induced activation of HIF-1:targeted molecular dynamics (TMD) [28] was used to convert the
free (initial structure) into the bound (reference structure) conforma- role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 460, 251–256.
3. Segnitz, B., and Gehring, U. (1997). The function of steroid hor-tion. In TMD, the standard molecular mechanics force-field is sup-
plemented by an additional term based on the mass-weighted root- mone receptors is inhibited by the hsp90-specific compound
geldanamycin. J. Biol. Chem. 272, 18694–18701.mean-square deviation (RMSD) of a set of atoms compared to a
4. Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl,reference structure. The conformational transition was performed
F.U., and Pavletich, N.P. (1997). Crystal structure of an Hsp90-with an 800 ps TMD simulation employing a 1 kcal mol	1 force
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